Dicloxacillin Shortage: What Providers and Prescribers Need to Know in 2026

Dicloxacillin remains a valuable narrow-spectrum agent for methicillin-susceptible Staphylococcus aureus (MSSA) infections. However, its niche market position, the discontinuation of branded Dynapen, and a limited generic manufacturer base have created persistent, localized availability challenges that clinicians need to anticipate in 2026.

This briefing summarizes the current availability landscape, presents evidence-based prescribing alternatives, and outlines tools your practice can use to improve patient access.

Current Availability Status

As of 2026, the FDA Drug Shortages Database does not list an active national shortage of Dicloxacillin, and ASHP has not issued a formal shortage bulletin. Despite this, localized stock-outs are consistently reported by patients filling prescriptions across multiple geographies.

The root cause is structural rather than a discrete manufacturing failure: Dicloxacillin is a low-volume, niche generic antibiotic produced by a limited number of manufacturers. Pharmacy ordering is demand-driven, and low turn rates mean thin stock buffers. A single prescription event at a small pharmacy can exhaust local supply.

Supply Chain Context

The broader antibiotic supply chain has faced sustained stress since the respiratory virus surges of 2022-2023. As of early 2026, the American Society of Health-System Pharmacists reported 216 medications in shortage or at risk nationally. While Dicloxacillin has not been among the most prominently affected, prescribers operating in this environment should plan for the possibility that first-line prescriptions may not be fillable on the same day.

The generic-only market for Dicloxacillin (following Dynapen's discontinuation) means there is no branded product buffering supply. Active pharmaceutical ingredient (API) sourcing is primarily overseas, adding vulnerability to regulatory inspections and international supply disruptions.

Evidence-Based Prescribing Alternatives

When Dicloxacillin is unavailable, the following alternatives are supported by clinical evidence and major guideline bodies:

Cephalexin (First-Line Equivalent for MSSA SSTIs)

Cephalexin is considered clinically equivalent to Dicloxacillin for mild-to-moderate MSSA skin and soft tissue infections (SSTIs). The IDSA guidelines for SSTIs list both agents as appropriate options. A randomized controlled study published in the Journal of the American Academy of Dermatology found cephalexin and dicloxacillin equally effective for staphylococcal skin infections, with cephalexin offering the additional advantage of twice-daily dosing.

Dose: 500 mg PO twice daily (non-purulent) or 500 mg PO four times daily (purulent), 5-7 days

Advantages: Universally available, can be taken with food, available in suspension for pediatrics, excellent safety profile

Caveat: Use with caution in patients with anaphylactic penicillin allergy due to potential (low) cross-reactivity

TMP-SMX (When MRSA Coverage Is Needed)

In purulent SSTIs where MRSA cannot be excluded, TMP-SMX (1-2 DS tablets PO BID for 5-7 days) provides coverage against both MSSA and community-acquired MRSA. IDSA guidelines support TMP-SMX as a preferred agent for purulent SSTIs. Local resistance surveillance should inform empiric choice.

Clindamycin (MSSA and MRSA; Penicillin-Allergic Patients)

Clindamycin (300-450 mg PO TID) is an appropriate alternative for patients with penicillin or cephalosporin allergies. It covers both MSSA and many MRSA strains. Inducible clindamycin resistance (D-zone test) should be checked when erythromycin-resistant isolates are identified.

Doxycycline (Alternative When Tetracycline Resistance Is Low)

Doxycycline (100 mg PO BID) is an option for MRSA-capable coverage in areas with low local tetracycline resistance. It is not reliably effective against streptococcal skin infections, so it is best reserved for confirmed or suspected MSSA/MRSA infections, not mixed or streptococcal cellulitis.

Antibiotic Stewardship Considerations

When switching from Dicloxacillin to an alternative due to availability, clinicians should document the rationale and confirm culture sensitivity data when available. Avoid broad-spectrum substitutes (fluoroquinolones, linezolid) for uncomplicated MSSA SSTIs. Prioritize agents with a spectrum matched to the clinical presentation.

Duration of therapy for uncomplicated SSTIs is typically 5-7 days; evidence does not support longer courses for mild cases and shorter courses reduce resistance selection pressure.

Patient Access Tools

When Dicloxacillin is appropriate and the patient wants to fill as prescribed, medfinder for Providers offers a tool to identify which nearby pharmacies have the medication in stock. The service calls pharmacies on the patient's behalf and texts results directly, reducing the burden on office staff to facilitate prescription transfers.

Coordinating with your local pharmacies about typical stock levels for Dicloxacillin can also streamline the prescribing process. Some independent pharmacies can maintain reliable stock if pre-ordered for expected patient demand.